ArticleCancers2022
Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Novel PSCA-Targeting Adapter Molecules for Late-Stage RevCAR-T Cell Therapy in Prostate Cancer.International journal of molecular sciences · 2026Article
- Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics.EJNMMI research · 2025Review
- CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives.Biomedicines · 2025Review
- CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells.International journal of molecular sciences · 2025Article
- Different PSMA Radiopharmaceuticals: A Comparative Study of [Pharmaceuticals (Basel, Switzerland) · 2024Article
- RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma.Cancer gene therapy · 2024Article
- Significance of PSCA as a novel prognostic marker and therapeutic target for cancer.Cancer cell international · 2024Review
- Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.EJNMMI radiopharmacy and chemistry · 2024Review
- Alpha-Emitting Radionuclides: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.Frontiers in immunology · 2023Article
- Tumor buster - where will the CAR-T cell therapy 'missile' go?Molecular cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 7 institutions in 3 countries.
Funding
Abstract
Due to its overexpression on the surface of prostate cancer (PCa) cells, the prostate stem cell antigen (PSCA) is a potential target for PCa diagnosis and therapy. Here we describe the development and functional characterization of a novel IgG4-based anti-PSCA antibody (Ab) derivative (anti-PSCA IgG4-TM) that is conjugated with the chelator DOTAGA. The anti-PSCA IgG4-TM represents a multimodal immunotheranostic compound that can be used (i) as a target module (TM) for UniCAR T cell-based immunotherapy, (ii) for diagnostic positron emission tomography (PET) imaging, and (iii) targeted alpha therapy. Cross-linkage of UniCAR T cells and PSCA-positive tumor cells via the anti-PSCA IgG4-TM results in efficient tumor cell lysis both in vitro and in vivo. After radiolabeling with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.